“Print-Age” An integrated approach for the promotion of health of old and fragile people: infections prevention, nutritional integration and personalized therapy

Print-Age is a POR MARCHE FESR 2014-2020 funded project (Asse 1 – Obiettivo Specifico 3 – Azione 3.1: “Promuovere soluzioni innovative per affrontare le sfide delle comunità locali nell’ambito della salute e benessere” for a total budget of about € 1,680,000 and a contribution of € 847,889.63.

The project partnership includes companies and clinical investigators located in Marche Region. The following companies: Diatheva, Diatech Pharmacogenetics and Mivell, in order to exploit the scientific and industrial expertise in the field of diagnostics and nutraceutics, will create a synergy through an active collaboration with leading research centers, represented by the Università di Urbino “Carlo Bo” and the Università Politecnica delle Marche. The specific objective is to develop products that will be used through an integrated approach to improve the health of fragile and elderly people, optimizing, at the same time, public health expenditure.
Companies will also have the opportunity to test their products, in development, under real conditions (living labs). This will happen in private health care facilities for rehabilitation (Gruppo Santo Stefano, Porto Potenza Picena), in public health facilities for the care of older people” (Istituto Nazionale di Ricovero e Cura per Anziani, INRCA) and in structure for the acute management of fragile people (Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona).

Diatheva is the project leader and will coordinate all the research and experimentation activities concerning the development of:

• Diagnostic kit for personalized medicine;
• Diagnostic kits for the prevention of clinical risk in healthcare facilities;
• Nutraceuticals for vulnerable people.

The role of Diatech Pharmacogenetics concerns the development of a diagnostic kit to support personalized treatments of vulnerable people. The research activity will be performed by using the MassARRAY technology and the validation for in vitro diagnostic use will be actuated following the 98/79/EC directive.
The final product will allow to analyze:

• Genetic polymorphisms that determine familiarity for cardiovascular diseases;
• Genetic polymorphisms predicting efficacy, toxicity and resistance to statins and likely predicting response to lipid-lowering nutraceuticals;
• Polymorphisms of genes involved into lipid metabolism, in inflammatory response and antioxidant defense system.

The diagnostic and predictive value of the markers analyzed by the kit will be established in the clinical trials coordinated by INRCA.

Poster download